Supernus Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SUPN research report →
Companywww.supernus.com
Supernus Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
- CEO
- Jack A. Khattar
- IPO
- 2012
- Employees
- 674
- HQ
- Rockville, MD, US
Price Chart
Valuation
- Market Cap
- $2.83B
- P/E
- -96.73
- P/S
- 3.64
- P/B
- 2.61
- EV/EBITDA
- 61.73
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 89.42%
- Op Margin
- -5.37%
- Net Margin
- -3.74%
- ROE
- -2.73%
- ROIC
- -2.16%
Growth & Income
- Revenue
- $718.95M · 8.63%
- Net Income
- $-38,550,000 · -152.19%
- EPS
- $-0.68 · -150.75%
- Op Income
- $-36,864,000
- FCF YoY
- -73.14%
Performance & Tape
- 52W High
- $59.68
- 52W Low
- $30.83
- 50D MA
- $50.13
- 200D MA
- $48.68
- Beta
- 0.57
- Avg Volume
- 722.27K
Get TickerSpark's AI analysis on SUPN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 16, 26 | Bhatt Padmanabh P. | other | 5,000 |
| Mar 17, 26 | Bhatt Padmanabh P. | other | 15,000 |
| Mar 16, 26 | Bhatt Padmanabh P. | other | 18,000 |
| Mar 17, 26 | Bhatt Padmanabh P. | other | 12,250 |
| Mar 16, 26 | Bhatt Padmanabh P. | other | 4,250 |
| Mar 16, 26 | Bhatt Padmanabh P. | other | 22,750 |
| Mar 17, 26 | Bhatt Padmanabh P. | other | 22,750 |
| Mar 17, 26 | Bhatt Padmanabh P. | sell | 27,710 |
| Mar 16, 26 | Bhatt Padmanabh P. | sell | 34,114 |
| Mar 18, 26 | Bhatt Padmanabh P. | other | 7,250 |
Our SUPN Coverage
We haven't published any research on SUPN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SUPN Report →